MedTrace Logo

Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy

NCT06558084 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2024-08-16

No results posted yet for this study

Summary

To assess CDK4/6i toxicity and effect on PFS in the Egyptian population

Conditions

  • Toxicity, Drug
  • Progression, Disease

Interventions

DRUG

CDK4/6 Inhibitor

CDK4/6 inhibitor in first and second lines

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-06
Primary Completion
2024-07-31
Completion
2024-08-10
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06558084 on ClinicalTrials.gov